Omeros Corporation Company Profile (NASDAQ:OMER)

About Omeros Corporation (NASDAQ:OMER)

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:OMER
  • CUSIP: 68214310
  • Web:
  • Market Cap: $952.51 million
  • Outstanding Shares: 44,803,000
Average Prices:
  • 50 Day Moving Avg: $21.36
  • 200 Day Moving Avg: $18.18
  • 52 Week Range: $7.20 - $27.09
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.37
  • P/E Growth: -0.19
Sales & Book Value:
  • Annual Revenue: $53.6 million
  • Price / Sales: 17.77
  • Book Value: ($1.23) per share
  • Price / Book: -17.28
  • EBIDTA: ($48,150,000.00)
  • Net Margins: -117.61%
  • Return on Assets: -62.51%
  • Debt-to-Equity Ratio: -1.49%
  • Current Ratio: 2.15%
  • Quick Ratio: 2.11%
  • Average Volume: 975,762 shs.
  • Beta: 3.54
  • Short Ratio: 11.73

Frequently Asked Questions for Omeros Corporation (NASDAQ:OMER)

What is Omeros Corporation's stock symbol?

Omeros Corporation trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros Corporation's earnings last quarter?

Omeros Corporation (NASDAQ:OMER) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million for the quarter, compared to analysts' expectations of $14.63 million. The firm's revenue for the quarter was up 71.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.32) earnings per share. View Omeros Corporation's Earnings History.

When will Omeros Corporation make its next earnings announcement?

Omeros Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Omeros Corporation.

Where is Omeros Corporation's stock going? Where will Omeros Corporation's stock price be in 2017?

7 equities research analysts have issued twelve-month price targets for Omeros Corporation's shares. Their predictions range from $8.63 to $75.00. On average, they expect Omeros Corporation's share price to reach $33.38 in the next year. View Analyst Ratings for Omeros Corporation.

What are analysts saying about Omeros Corporation stock?

Here are some recent quotes from research analysts about Omeros Corporation stock:

  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (7/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)
  • 4. Maxim Group analysts commented, "Omeros announced a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compassionate-use protocol. The presentation 'Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient' occurred at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation in Marseille, France on Monday, March 27, 2017. OMS721 continues to demonstrate positive data across multiple indications that are associated with complement. What differentiates OMS721 from other complement inhibitors like Alexion's Soliris, is the ability to target just a single arm of the complement system (lectin pathway) which leaves the rest of the system intact for important functions like protecting against infections." (3/27/2017)
  • 5. Needham & Company LLC analysts commented, "OMER's 4Q16 results, driven by Omidria sales that slightly bested consensus, came slightly ahead of Street expectations. Omidria sales are now annualizing at ~$52MM, which gives us confidence that sales can ramp up to the mid-$60MM range in 2017. Our concern with Omidria rests with the transitional passthrough reimbursement that potentially expires on 1/1/2018. If reimbursement is not extended, Omidria will likely be reimbursed as part of a procedural bundled payment, which would likely impact its current price. On the pipeline front, the OMS721 ph 3 trial for aHUS is now open for enrollment. We continue to view the pipeline (esp. OMS721) as a key value growth driver for OMER, though one that requires additional clinical data for validation. We maintain our Buy rating and adjust our PT to $22 (from $24)." (3/17/2017)

Who are some of Omeros Corporation's key competitors?

Who are Omeros Corporation's key executives?

Omeros Corporation's management team includes the folowing people:

  • Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer
  • Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary
  • Thomas J. Cable, Lead Independent Director
  • Peter A. Demopulos M.D., Director
  • Ray Aspiri, Independent Director
  • Arnold C. Hanish, Independent Director
  • Leroy E. Hood M.D., Ph.D., Independent Director

Who owns Omeros Corporation stock?

Omeros Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (11.71%), Vanguard Group Inc. (4.16%), State Street Corp (2.20%), American Financial Group Inc. (1.63%), Northern Trust Corp (1.30%) and Tocqueville Asset Management L.P. (1.09%). Company insiders that own Omeros Corporation stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros Corporation.

Who sold Omeros Corporation stock? Who is selling Omeros Corporation stock?

Omeros Corporation's stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO., Tocqueville Asset Management L.P., The Manufacturers Life Insurance Company , Stoneridge Investment Partners LLC, New York State Common Retirement Fund, Nationwide Fund Advisors, Candriam Luxembourg S.C.A. and Capital Impact Advisors LLC. Company insiders that have sold Omeros Corporation stock in the last year include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros Corporation.

Who bought Omeros Corporation stock? Who is buying Omeros Corporation stock?

Omeros Corporation's stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC, Quantitative Investment Management LLC, Stifel Financial Corp, Vanguard Group Inc., State Street Corp, Capital Analysts LLC, Ingalls & Snyder LLC and Ameriprise Financial Inc.. View Insider Buying and Selling for Omeros Corporation.

How do I buy Omeros Corporation stock?

Shares of Omeros Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros Corporation's stock price today?

One share of Omeros Corporation stock can currently be purchased for approximately $21.26.

MarketBeat Community Rating for Omeros Corporation (NASDAQ OMER)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  365 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  527
MarketBeat's community ratings are surveys of what our community members think about Omeros Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Omeros Corporation (NASDAQ:OMER) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.38 (56.99% upside)

Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 -> $19.00HighView Rating Details
8/18/2017WedbushReiterated RatingOutperform$47.00LowView Rating Details
8/8/2017Maxim GroupReiterated RatingBuy$23.00 -> $24.00HighView Rating Details
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00HighView Rating Details
6/3/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for Omeros Corporation (NASDAQ:OMER)
Earnings by Quarter for Omeros Corporation (NASDAQ:OMER)
Earnings History by Quarter for Omeros Corporation (NASDAQ OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.36)N/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.33
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.34)($0.35)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.12)($0.20)
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.03$0.03$0.03
Q3 20181$0.14$0.14$0.14
Q4 20181$0.18$0.18$0.18
(Data provided by Zacks Investment Research)


Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Omeros Corporation (NASDAQ:OMER)
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 44.93%
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.00View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.00View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.00View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Omeros Corporation (NASDAQ:OMER)
Latest Headlines for Omeros Corporation (NASDAQ:OMER)
DateHeadline logoOmeros Corporation (OMER) Receives Consensus Recommendation of "Buy" from Brokerages - September 23 at 4:38 PM logoETFs with exposure to Omeros Corp. : September 22, 2017 - September 23 at 9:06 AM logoSpeech Language Pathologist Named National Staffing Employee of the Year - September 19 at 6:12 AM logoETFs with exposure to Omeros Corp. : September 12, 2017 - September 12 at 8:14 AM logoOmeros - Stay The Course - Seeking Alpha - September 8 at 6:45 AM logoETFs with exposure to Omeros Corp. : August 31, 2017 - September 1 at 6:47 AM logoOmeros Corporation (OMER) Receives Average Rating of "Buy" from Brokerages - August 29 at 4:44 PM logoOmeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 26 at 7:59 AM logoOmeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 26 at 7:59 AM logoOmeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017 - August 24 at 10:38 AM logoOmeros Responds to Story - August 24 at 10:38 AM logoOmeros Co. (OMER) Given "Hold" Rating at Cantor Fitzgerald - August 24 at 8:46 AM logoOmeros Closes $68.3 Million Public Offering of Common Stock - Business Wire (press release) - August 23 at 9:45 AM logoOmeros Shares Lower After Completing Stock Offering, Juno Dips ... - - August 23 at 9:45 AM logoSTAT's Feuerstein questions Omeros' OMS721, shares down 2% premarket - August 22 at 7:25 AM logoOmeros Closes $68.3 Million Public Offering of Common Stock - August 22 at 2:23 AM logoA Balanced Take On Omeros - August 22 at 2:23 AM logoQ2 2018 EPS Estimates for Omeros Corporation Reduced by Analyst (OMER) - August 21 at 6:46 AM logoOmeros Corporation (OMER) Given Outperform Rating at Wedbush - August 18 at 7:38 AM logoSeattle’s third-largest biotech seeks $70 million in stock offering - August 18 at 6:48 AM logoOmeros (OMER) Prices 3M Common Stock Offering at $22.75/Share - August 16 at 6:29 AM logoOmeros Announces Pricing of Public Offering of Common Stock - August 16 at 6:28 AM logoOmeros's stock sinks after share offering prices at a discount - August 16 at 6:28 AM logoOmeros (OMER) Commences 3M Common Stock Offering - August 15 at 5:43 AM logoOmeros Corp. (OMER) Is Heading Lower After Offering Announcement - August 15 at 5:43 AM logoOmeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721 - August 15 at 5:43 AM logoOmeros Announces Public Offering of Common Stock - August 15 at 5:43 AM logoOmeros Hoists Sales - August 11 at 7:13 AM logoOmeros to Present at the 2017 Wedbush PacGrow Healthcare Conference - August 11 at 7:13 AM logoToday's Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals - August 11 at 7:13 AM logoOmeros' (OMER) CEO Greg Demopulos on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 9 at 6:04 AM logoOmeros Corporation Reports Second Quarter 2017 Financial Results - Business Wire (press release) - August 9 at 6:04 AM logoOmeros Corporation Reports Second Quarter 2017 Financial Results - August 9 at 6:03 AM logoOmeros Corporation Reports Second Quarter 2017 Financial Results - August 9 at 6:03 AM logoOmeros reports 2Q loss - August 9 at 6:03 AM logoOmeros reports 2Q loss - August 9 at 6:03 AM logoEdited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT - August 9 at 6:03 AM logoEdited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT - August 9 at 6:03 AM logoOmeros Corporation (OMER) Earns Buy Rating from Maxim Group - August 8 at 8:56 PM logoOmeros Corporation (NASDAQ:OMER) Issues Quarterly Earnings Results - August 8 at 6:50 PM logoOmeros (OMER) Announces FDA Grants Orphan Drug Designation for OMS721 for Treatment of IgA Nephropathy - August 5 at 5:28 AM logoFDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy - August 5 at 5:28 AM logoOmeros Corporation (OMER) Receives Consensus Recommendation of "Buy" from Analysts - August 4 at 7:08 PM logoOmeros' OMS721 an Orphan Drug in U.S. for IgA nephropathy; shares ahead 3% - August 4 at 11:39 AM logoOmeros Corporation (NASDAQ:OMER) to Release Earnings on Tuesday - August 3 at 11:27 AM logoOmeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017 - August 3 at 6:36 AM logoOmeros Corporation (OMER) Given a $24.00 Price Target by Maxim Group Analysts - August 2 at 6:28 PM logoValue Investment Stock Selections Using Forensic Analysis - July - Seeking Alpha - July 24 at 2:24 PM logoOmeros wins court order against Twitter critic whose accusations caused stock to drop - July 21 at 5:30 AM logoToday's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation - July 17 at 9:14 AM



Omeros Corporation (OMER) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff